iRhythm Technologies (IRTC) Competitors

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Do analysts prefer TNDM or IRTC?

Tandem Diabetes Care presently has a consensus price target of $50.58, indicating a potential upside of 3.55%. iRhythm Technologies has a consensus price target of $134.00, indicating a potential upside of 40.08%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
iRhythm Technologies	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, TNDM or IRTC?

Tandem Diabetes Care has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Which has stronger valuation & earnings, TNDM or IRTC?

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$747.72M	4.22	-$222.61M	-$2.17	-22.51
iRhythm Technologies	$513.17M	5.80	-$123.41M	-$4.23	-22.61

Does the MarketBeat Community favor TNDM or IRTC?

Tandem Diabetes Care received 183 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.04% of users gave iRhythm Technologies an outperform vote while only 61.18% of users gave Tandem Diabetes Care an outperform vote.

Company	Underperform	Outperform
Tandem Diabetes Care	Outperform Votes 572 61.18%	Underperform Votes 363 38.82%
iRhythm Technologies	Outperform Votes 389 66.04%	Underperform Votes 200 33.96%

Is TNDM or IRTC more profitable?

Tandem Diabetes Care has a net margin of -18.37% compared to Tandem Diabetes Care's net margin of -25.33%. iRhythm Technologies' return on equity of -34.38% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%
iRhythm Technologies	-25.33%	-69.87%	-23.50%

Does the media prefer TNDM or IRTC?

In the previous week, iRhythm Technologies had 5 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 14 mentions for iRhythm Technologies and 9 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.84 beat iRhythm Technologies' score of 0.81 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care beats iRhythm Technologies on 9 of the 16 factors compared between the two stocks.